NeoStem is developing therapeutics that target cancer initiating cells, starting with a Phase 3 trial for melanoma.
Enhancingthe body’s healing response
Rebalancingthe immune system
Unlockingthe power of VSELs
NeoStem is exploring the therapeutic potential of very small embryonic-like stem cells (VSELsTM) to regenerate or repair damaged or diseased tissues.
NeoStem’s Investigational Targeted Cancer Immunotherapy For Late Stage Melanoma (2 minute)
See how NeoStem's Phase III investigational targeted cancer immunotherapy, NBS20 (eltrapuldencel-T), is created and administered. The product candidate is being evaluated for the treatment of patients suffering from late stage malignant melanoma.
News + EventsNeoStem Announces Addition of Experienced Scientist and Biotechnology Executive Peter G. Traber, MD, to Its Board of Directors January 22, 2015 - Learn MoreNeoStem Receives Drug Manufacture License for Irvine Facility January 20, 2014 - Learn MoreNeoStem and Invetech Announce Agreement to Develop Closed Processing System for Cell Therapy Manufacturing January 12, 2015 - Learn More
After an extensive search, it is with great pleasure that I have the opportunity today to introduce Dr. Dav.... Read More
We are particularly encouraged by the results of our PreSERVE AMI trial both from our own reading of the in.... Read More